HBHeather A. Berlin

Heather A. Berlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heather A. Berlin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Hollander

    Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA

    3 shared publications
  • David Rosenthal

    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    2 shared publications
  • Lorrin M. Koran

    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA, USA

    2 shared publications
  • Rachel Turetzky

    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    2 shared publications
  • Sam Zhang

    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    2 shared publications
  • Stefano Pallanti

    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

    2 shared publications

Latest Publications

  • Altered olfactory processing and increased insula activity in patients with obsessive-compulsive disorder: An fMRI study

    by Heather A. Berlin, Emily R. Stern, Johnny Ng, Sam Zhang, David Rosenthal, Rachel Turetzky, Cheuk Tang, Wayne Goodman


  • Neural correlates of emotional response inhibition in obsessive-compulsive disorder: A preliminary study

    by Heather A. Berlin, Kurt P. Schulz, Sam Zhang, Rachel Turetzky, David Rosenthal, Wayne Goodman


  • Open Access

    Implicit Self-Esteem in Borderline Personality and Depersonalization Disorder

    by Alexis N. Hedrick, Heather A. Berlin

    Self-perception is disrupted in people with borderline personality disorder (BPD) and depersonalization disorder (DPD), fluctuating with sudden shifts in affect in BPD and experienced as detached in DPD. Measures of implicit self-esteem (ISE), free from conscious control and presentation biases, may highlight how such disruptions of self-concept differentially affect these two populations on an unconscious level. We examined ISE using the Implicit Association Test, along with measures of emotion, behavior, and temperament, in BPD (n = 18), DPD (n = 18), and healthy control (n = 35) participants. DPD participants had significantly higher ISE and were more harm avoidant than BPD and control participants, while BPD participants had more “frontal” behaviors and impulsivity and less self-directedness and cooperativeness than DPD and control participants. Thus, while BPD and DPD commonly overlap in terms of dissociative symptoms and emotional irregularities, differences in self-esteem, behavior, and temperament can help identify where they diverge in terms of their cognition, behavior, and ultimately underlying neurobiology.


  • A double-blind, placebo-controlled trial of topiramate for pathological gambling

    by Heather A. Berlin, Ashley Braun, Daphne Simeon, Lorrin M. Koran, Marc N. Potenza, Susan L. McElroy, Timothy Fong, Stefano Pallanti, Eric Hollander

    Objectives. Pathological gambling (PG) is an impulse control disorder characterized by recurrent gambling thoughts and behaviours that impair social functioning. Earlier studies suggested that topiramate may be effective in treating some impulse control disorders. We conducted the first randomized, controlled trial of topiramate in PG. Methods. PG patients were randomized to topiramate (N = 20) or placebo (N = 22) in this 14-week, double-blind, placebo-controlled, parallel-group trial. The primary outcome measure was change in the obsessions subscale of the Yale-Brown Obsessive-Compulsive Scale Modified for Pathological Gambling. Results. Mixed regression models (time [weeks] × treatment) revealed no significant treatment effect of topiramate on the primary or secondary outcome measures. The most statistically robust findings involved reducing the Barratt Impulsiveness Scale (BIS) total score and Motor and Non-Planning subscale scores, for which topiramate outperformed placebo at merely a trend level (P < 0.1). Conclusions. The observed trend in BIS score reductions may warrant further investigation to study whether topiramate reduces clinically important impulsivity in PG. Treatment studies with larger samples and less stringent exclusion criteria are needed to produce results that can be generalized to pathological gamblers in the community.


  • The Neural Basis of the Dynamic Unconscious

    by Heather A. Berlin

    A great deal of complex cognitive processing occurs at the unconscious level and affects how humans behave, think, and feel. Scientists are only now beginning to understand how this occurs on the neural level. Understanding the neural basis of consciousness requires an account of the neural mechanisms that underlie both conscious and unconscious thought, and their dynamic interaction. For example, how do conscious impulses, thoughts, or desires become unconscious (e.g., repression) or, conversely, how do unconscious impulses, desires, or motives become conscious (e.g., Freudian slips)? Research taking advantage of advances in technologies, like functional magnetic resonance imaging, has led to a revival and re-conceptualization of some of the key concepts of psychoanalytic theory, but steps toward understanding their neural basis have only just commenced. According to psychoanalytic theory, unconscious dynamic processes defensively remove anxiety-provoking thoughts and impulses from consciousness in response to one’s conflicting attitudes. The processes that keep unwanted thoughts from entering consciousness include repression, suppression, and dissociation. In this literature review, studies from psychology and cognitive neuroscience in both healthy and patient populations that are beginning to elucidate the neural basis of these phenomena are discussed and organized within a conceptual framework. Further studies in this emerging field at the intersection of psychoanalytic theory and neuroscience are needed.


  • Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

    by Heather A. Berlin, Lorrin M. Koran, Michael A. Jenike, Nathan A. Shapira, William Chaplin, Stefano Pallanti, Eric Hollander

    From 40% to 60% of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. Using mixed regression models (time [weeks] × treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28% (5/18) of the subjects discontinued the drug for adverse effects, and 39% (7/18) had a dose reduction for this reason. The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. clinicaltrials.gov Identifier: NCT00211744.


  • Antiepileptic Drugs for the Treatment of Impulsivity

    by Heather A. Berlin

    Evidence is reviewed here which suggests that antiepileptic drugs (AEDs) may be effective for the treatment of impulsivity across a range of psychiatric disorders and for impulse control and cluster B personality disorders in particular. AEDs may be effective for the treatment of the brain circuitry related to impulsivity, by modulating GABA, glutamate, serotonin, and norepinephrine. It is suggested that interventions should be directed at the brain circuitry which modulates core symptoms like impulsivity that may be shared across disorders, rather than the disorder itself. In addition to these core symptom domains, clinicians should identify comorbid conditions and associated symptoms related to brain systems as they can also influence overall treatment response. The increasing experience of psychiatrists in treating impulse control disorders, cluster B personality disorders, and impulsivity across disorders should complement the knowledge obtained from research. This will lead to a better understanding of the brain mechanisms underlying impulsive symptom domains within disorders and to more targeted treatments with improved outcomes.


  • Experimental therapeutics for refractory obsessive‐compulsive disorder: translational approaches and new somatic developments

    by Heather A. Berlin, Holly Hamilton, Eric Hollander

    Significant advances over the past 20 years in our understanding of the phenomenology and pathophysiology of obsessive‐compulsive disorder, made in part from structural and functional neuroimaging and genetics research, can guide treatments that target brain regions, circuits, and neurotransmitter systems specific to obsessive‐compulsive disorder, the disruption of which may alleviate obsessive‐compulsive disorder symptoms. We discuss here our current understanding of the underlying neurobiology and heritability of obsessive‐compulsive disorder and integrate that understanding with a review of the current pharmacological, neurosurgical, and brain stimulation treatments of refractory obsessive‐compulsive disorder. Expanding on these studies, we hope that new pharmacological and psychological treatment strategies and research‐driven targets for lesioning, stimulation, or other types of focal neuromodulation can be identified that could lead to future research directions. Cross‐species translational research and neuroimaging of the physiological and anatomical pathways implicated in the pathophysiology and treatment response in obsessive‐compulsive disorder will advance our understanding of the neural basis of obsessive‐compulsive disorder and lead to more targeted and effective treatment options. Mt Sinai J Med 75:174–202, 2008. © 2008 Mount Sinai School of Medicine


  • Antiepileptic drugs for the treatment of post-traumatic stress disorder

    by Heather A. Berlin

    Post-traumatic stress disorder (PTSD) is a disruptive, chronic, and relatively common disorder that is often difficult to treat. Many patients with PTSD are unresponsive, have only moderate or marginal responses, or have troubling side effects to first-line serotonin reuptake inhibitor treatment. Studies suggest that antiepileptic drugs (AEDs) may be an effective treatment alternative or adjunctive treatment for the symptoms of PTSD. Recent results from case reports and open and controlled studies on the efficacy and tolerability of AEDs in PTSD are reviewed here, and their methodological limitations are discussed when relevant. AEDs shown to be effective in double-blind, placebo-controlled trials of PTSD include lamotrigine, topiramate, and tiagabine. Other AEDs that appear promising in open-label trials of PTSD include carbamazepine, valproate, gabapentin, vigabatrin, phenytoin, and levetiracetam. Stress-activated limbic kindling may be involved in the pathogenesis of PTSD. The possibility that AEDs may be effective in the treatment of PTSD due to their antikindling effect is discussed, and suggestions for future research are made.